Kornimate/medical-research-clean huggingface dataset:
a new technique to diagnose acute and chronic deep vein thrombosis

Conditions: Deep Vein Thrombosis; Compression Ultrasound; Elastography; Elasticity Imaging Techniques

Summary: in clinical practice, compression ultrasound (cus) has become an easy and reliable noninvasive tool for the diagnosis of deep vein thrombosis (dvt). currently there are not validated methods to assess the biological age of venous thrombus, and the date of onset of thrombosis. one potential technique to age dvt is ultrasound elastography (ue). ue is a noninvasive technique to measure tissue hardness, and it is well known that thrombi harden as they age. the aim of this study will be to assess the ability of ue to distinguish acute from chronic dvt. the investigators will evaluate prospectively all consecutive outpatients presenting with clinically suspected unprovoked dvt of the lower limbs, and those having a previous diagnosis of dvt for the scheduled 3 months visit of follow-up, for a period of about one year. all the enrolled patients will undergo to the cus of the lower limbs, and at the same time to the ultrasound elastography by the physician expert in vascular ultrasound. the specialist performing both examinations will be unaware of the time of onset of dvt (acute or chronic). then the patients will be divided into two groups (group a: patients with acute dvt; group b: patients with chronic dvt at the 3rd month of follow-up). each examination (cus and ultrasound elastography) will be repeated three times in the same patient at the same visit, to assess the reproducibility of the technique. the demographic data, medical history, physical examination and the results of cus and ultrasound elastography will be collected in a case report form (crf) by another investigator who does not perform the examinations. the blinded crf will be submitted to a dedicated committee for statistical analysis.


Eligibility criteria:
inclusion criteria: * acute first episode of unprovoked dvt of lower limbs * chronic first episode of unprovoked dvt of lower limbs (at third month of follow up) exclusion criteria: * previous episodes of dvt * ongoing anticoagulation * age younger than 18 years * pregnancy
frailty in patients with gastrointestinal cancer who are undergoing major surgery

Conditions: Gastrointestinal Cancer

Summary: this research is for patients who have gastrointestinal cancer and have a planned major surgery. the purpose of this research is to identify cancer patients who may be at risk for frailty. frailty is common in older adults and may include symptoms of weight loss, weakness, fatigue, low activity, slow walking and other illnesses. frailty may increase the risk of problems after major surgery. the study will involve a survey, a blood sample, and a review of medical records.

the goals of the study are to: * describe the rate of frailty in surgical cancer patients * assess if frailty correlates with problems (adverse outcomes) after major surgery participants taking part will be asked to complete a survey to assess frailty before surgery. the frailty survey is referred to as the clinical risk analysis index (rai-c). participants will have about 10 ml (2 teaspoons) of blood drawn before surgery. blood tests will include complete blood count (cbc), vitamin a, creatinine, c-reactive protein (crp), dhea, albumin, and prealbumin.

Eligibility criteria:
inclusion criteria: * 18 years old or older * histologically proven gastrointestinal malignancy * referral for elective major surgical procedures at including operations for upper and lower gastrointestinal malignancies and hepato-pancreato-biliary * referral for neoadjuvant treatment followed by any of the above major surgical procedures exclusion criteria: * under 18 years * pregnant women
non-persistence/non-adherence (np/na) in wet age-related macular degeneration (wamd) patients in germany

Conditions: Wet Macular Degeneration

Summary: in the research study an observation of patients with wet age-related macular degeneration (wet amd) will be performed. the term observational study indicates that the current course of therapy and the associated circumstances will be recorded. in this study, no medical care is changed. also, no new drugs are tested. this study is being conducted in about 30 centers in germany. a total of approximately 500 patients will be enrolled. the study is designed for a period of 12 months. at the beginning and end of the study the physician will document the patient data. therefore will be used information from the patient records and documented visits. if such information is not available in the study center, the otherwise attending ophthalmologist will be consulted about the vision acuity values and visits in the observation period. furthermore, patients are asked to participate in three telephone interviews and fill out during their visits to the study center a short questionnaire about their current vision and their well-being. in the telephone interviews will be discussed with the patient about his wet amd disease and its treatment, its experience and its perspectives as well as any problems occur.


Eligibility criteria:
inclusion criteria: * patient has wet age-related macular degeneration (wamd) * patient has already received at least one anti-vegf injection * from a clinical standpoint, if there is an ophthalmological need for treatment it is probable that the patient gets additional anti-vegf injections in the next year. * the patient is able and willing to take part in the study (answering a short questionnaire in the study centre, 4 independent phone interviews during study period). exclusion criteria: * at time of inclusion visit, the study centre is only exceptionally responsible for the treatment of the patient. * the patient is taking part in another study.

Keywords: medication non-adherence medication persistence wet macular degeneration
negative pressure wound therapy in healing abdominal incision in obese patients undergoing breast reconstruction surgery

Conditions: Body Mass Index Greater Than or Equal to 30; Malignant Breast Neoplasm; Mammoplasty Patient; Obesity

Summary: this trial studies the safety and how well negative pressure wound therapy works in healing the abdominal incision in obese patients undergoing free flap breast reconstruction surgery. using negative pressure wound therapy (npwt) instead of standard dressing (bandages) may improve wound healing at the surgical site in the abdomen where tissue was collected for breast reconstruction surgery.

primary objectives: i. determine the impact of negative pressure wound therapy on wound healing as measured by wound dehiscence rate. ii. long-term follow-up on wound healing complications. outline: patients are randomized to 1 of 2 groups. group i: patients receive wound care with a standard dressing (bandage) after surgery for 7 days. group ii: patients receive negative pressure wound therapy (npwt) after surgery for 7 days. after completion of study, patients are followed up at 2 weeks, and at 1 and 3 months.

Eligibility criteria:
inclusion criteria: * patients undergoing a free abdominal flap, including a superficial inferior epigastric artery (siea), deep inferior epigastric artery perforator (diep), or muscle-sparing transverse rectus abdominus myocutaneous (ms-tram) flap for breast reconstruction. * patients are willing and able to give consent. * body mass index (bmi) greater than or equal to 30.0. exclusion criteria: * patients who are unable to provide consent. * patients who are suspected or known to be pregnant. * known allergy to topical adhesives.
study of the metabolism of two magnesium supplements in healthy volunteers

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Summary: the present study is part of a project titled 'magnesium in asthma and chronic obstructive pulmonary disease'. the hypothesis of the main project is that daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease. the aim of this part of the project is to study the pharmacokinetics of the following two magnesium supplements: * mablet (dietary supplement) * magnesium sulfate (solution for infusion)


Eligibility criteria:
inclusion criteria: * healthy volunteers. exclusion criteria: * smokers, * using pharmaceuticals/supplements, * vegans/vegetarians, * major changes in eating habits within one week prior to study start.

Keywords: clearance half-life absorption fraction pharmacokinetics
effects of canagliflozin on c-peptide clearance in healthy volunteers

Conditions: Healthy

Summary: the purpose of this study is to assess whether treatment with a single oral 300 mg dose of canagliflozin alters the kinetics (ie, clearance/removal from body) of serum c-peptide (a protein released from the pancreas during insulin secretion) in healthy adult volunteers.

this is a double-blind (neither the volunteer nor the study doctor/staff will know the identity of the assigned treatments) study to assess the effect of single oral (taken by mouth) dose of canagliflozin on clearance (removal from the body) of c-peptide in healthy adult volunteers. healthy volunteers will be randomly (by chance) assigned to receive a single oral dose of canagliflozin followed by a single oral dose of placebo (inactive substance) or a single dose of placebo followed by a single dose of canagliflozin with a period of 7-10 days between treatments. healthy volunteers will also receive intravenous (i.v.) infusion (injection in the vein) of somatostatin for 4 hours and a single dose i.v. injection of synthetic human c-peptide following administration of canagliflozin or placebo during each treatment period. somatostatin will suppress the normal secretion of c-peptide, a protein that is released from the pancreas during insulin secretion, so that the human c-peptide administered to volunteers can be accurately measured. the total study duration for each volunteer will be approximately 44 days. during the study, blood and urine samples will be drawn (collected) for clinical laboratory evaluations.

Eligibility criteria:
inclusion criteria: * healthy volunteers with a body mass index (bmi, a measure of a person's weight in relation to height) between 18 and 30 kg/m2, inclusive, and a body weight of not less than 50 kg exclusion criteria: * history of or current clinically significant medical illness as determined by the investigator * history of clinically significant allergies, especially known hypersensitivity or intolerance to lactose * known allergy or clinically significant adverse reactions to canagliflozin or placebo or any of the excipients of the canagliflozin or placebo formulation * known hypersensitivity of synthetic human c-peptide, somatostatin preparation, or other structurally related peptides

Keywords: healthy clearance canagliflozin jnj-28431754 placebo somatostatin c-peptide
extent of ilm removal and its impact on outcomes of mh surgery

Conditions: Macular Holes

Summary: eligible patients who were scheduled for surgery for idiopathic macular hole (mh) were equally randomized to small extent group or large extent group depending on the extent of internal limiting membrane (ilm) to be removed. the ilm was peeled in round shape with the radius of either 0.75-disc diameter or 1.5-disc diameter according to the group. the primary analysis was conducted to identify the difference of functional and anatomical outcomes between the two groups. subsequent analysis was performed to reveal the relationship between the functional and anatomical outcomes.

this randomized clinical trial was performed at a single center. patients who were scheduled for surgery for idiopathic macular hole (mh) were enrolled. eligible patients were equally randomized to small extent group or large extent group depending on the extent of ilm to be removed. random numbers were generated through computerized block-randomization. a standard 3-port pars plana vitrectomy was performed by a single surgeon using 23-gauge vitrectomy system, with a 1-step scleral tunnel incision. after posterior vitreous detachment was achieved, peeling of the ilm was performed by an end gripping forceps with the assistance of indocyanine green dye. the ilm was peeled in round shape with the radius of either 0.75-disc diameter or 1.5-disc diameter centering at the center of the mh according to the pre-assigned group. this was followed by a complete fluid-gas exchange, and all patients were encouraged to maintain a face-down position for at least 5 days postoperatively. postoperative measurements of bcva and m-score were conducted at 2- and 6-month follow-up visits by independent masked observers. the first postoperative sd-oct scanning was usually conducted at 1 to 2 weeks after operation according to the intraocular gas status. then, oct scans were conducted at follow-up visits 2, and 6 months postoperatively. the same experienced examiner conducted all the oct scans on all subjects. comparison of anatomical closure, bcva, m-score, δ bcva, and δ m-score were primarily performed between the two groups. then, the parameters measured from oct scans with changes in etdrs visual acuity and m-score were analyzed.

Eligibility criteria:
inclusion criteria: * idiopathic macular hole exclusion criteria: * macular hole associated with other causative diseases

Keywords: internal limiting membrane metamorphopsia
collection of information to better understand young onset colorectal cancer

Conditions: Colorectal Cancer; Colorectal Carcinoma

Summary: the purpose of this registry study is to create a database-a collection of information-for better understanding young onset colorectal cancer. colorectal cancer patients are considered to have young onset colorectal cancer if they are diagnosed with their cancer before the age of 50. researchers will use the information from this database to learn more about how young onset colorectal cancer may be similar to or different from colorectal cancer that is diagnosed later in life. researchers will also use information from the database for current and future research on young onset colorectal cancer.


Eligibility criteria:
inclusion criteria: participant inclusion criteria for database and questionnaire (yogi) * histological or cytological diagnosis of gastrointestinal cancer * 18 - 49 years old at time of consent * no known hereditary crc or other cancer predisposition syndrome (stool collection cohort only) * no history of inflammatory bowel disease (stool collection cohort only) * no prior diagnosis of gastrointestinal cancer (stool collection cohort only) participant inclusion criteria for database and questionnaire (controls) * histological or cytological diagnosis of colorectal adenocarcinoma * no previous treatment for crc (including surgery, chemotherapy, immunotherapy or radiation) * age 50 or older at time of consent * no known hereditary crc or other cancer predisposition syndrome * no history of inflammatory bowel disease * no prior diagnosis of crc

Keywords: young onset colorectal cancer colorectal registry 20-315 memorial sloan kettering cancer center
evaluation of the intraoperative accuracy of 3d-planned and guided osteotomies of the hand and forearm

Conditions: Posttraumatic or Congenital Bone Deformity

Summary: target of the study is to evaluate the reduction accuracy of 3d computer-planned osteotomies that are performed with patient-specific instruments. due to the higher accuracy achieved it is expected that complaints can be resolved or effectively revealed. the research hypothesis to prove is "the medical product permits the surgical reduction of deformed bones of the hand and forearm (radius, ulna, distal humerus, carpal, metacarpal, and finger bones) by corrective osteotomy within an accuracy of 2 mm and 2º. secondary outcome is an assessment of the surgical outcome using the "disabilities of the arm, shoulder and hand" (dash) and the "patient related wrist evaluation" (prwe) scores.


Eligibility criteria:
inclusion criteria * posttraumatic or congenital bone deformity or pseudoarthrosis in the field of hand surgery requiring correction by corrective osteotomy * clinical indication for a computer tomography scan of the forearms * \> 18 years old * written informed consent exclusion criteria * pregnant or nursing women * other clinical significant accompanying symptoms (tumor, infection) * non-compliance of the patient to follow the clinical study protocol, drug or alcohol abuse * participation in a different clinical trial within the last 30 days before inclusion or during the study
masitinib in relapse or refractory multiple myeloma with t(4/14) translocation expressing or not fgfr3

Conditions: Multiple Myeloma

Summary: this phase 2 study was designed to assess the safety and efficacy of masitinib (ab1010) in patients with relapsing/refractory t(4;14) multiple myeloma. response and progression were assessed according to the bladé revised imwg criteria1 from lowest point.


Eligibility criteria:
inclusion criteria: * confirmed multiple myeloma with a t (4; 14) translocation by fish and pcr, expressing or not expressing fgfr3 identified by facs * patients with multiple myeloma progressing or relapsing after at least two prior therapies (including conventional chemotherapy and/or high dose therapy) or who get a reduction of m-protein less than 75% within 3 months after a high dose treatment (melphalan 200mg/m2) or after the plateau obtained for 3 months duration following to a conventional chemotherapy * patient with rapidly progressive disease with cytopenia and / or renal failure have to be stabilized with chemotherapy (if possible 3 cycles of vtd ( bortezomib/thalidomide/dexamethasone) or high dose melphalan regimen followed by a 4 weeks washout period before the inclusion in the study. * patients must have a clearly detectable and quantifiable monoclonal m- component value (\>5 g/l) in the serum and / or urine light chain excretion (\>0,5 g/d) exclusion criteria: * prior corticosteroids within two weeks before enrolment * prior local irradiation within two weeks before enrolment * prior experimental or standard treatment (other than steroids and local irradiation) within 30 days before enrolment

Keywords: multiple myeloma t(4/14) relapsing refractory
effect of mindfulness training on sleep and inflammation among older adults with sleep problems

Conditions: Sleep Problems; Inflammation

Summary: the primary aim of the study is to test the effect of mindfulness training on sleep parameters among older adults with insomnia symptoms the secondary aims are to examine if changes in mindfulness meditation practice (daily log) and level of mindfulness (self-report) are associated with changes in sleep parameters, and to determine if mindfulness training is associated with in vitro biological markers of peripheral inflammation


Eligibility criteria:
inclusion criteria: * men and women (all races and ethnicities) 55 years of age and older * have current problems sleeping * fluent in english * able to understand and provide signed informed consent * willing to be randomly assigned to treatment condition exclusion criteria: * individuals currently undergoing major medical treatment such as surgery, radiation, or immunotherapy * individuals living outside of a 20 mile radius from the ucla medical center * individuals with current substance dependence

Keywords: sleep inflammation mindfulness meditation randomized controlled trial
the effect of smartphone addiction on trunk muscles performance in adolescents

Conditions: Smartphone Addiction; Muscle Weakness Condition; Adolescents

Summary: statement of the problem: does overuse of the smartphones affect trunk muscles performance in normal adolescents it will be assumed that there will be no affection of smartphone addiction on trunk muscles performance in normal adolescents

* subjects: - sixty - six normal healthy adolescent from both genders will be recruited for the study from high school students and first year university students, they will be divided according to their smart phone addiction scale short version (sas-sv) scores into two groups: group (a): smartphone addicts (consists of 33 participants) group (b): smartphone non- addicts (consists of 33 participants) * inclusion criteria * age ranges from 14 to 18 years * have body mass index (bmi) = 5th percentile to less than the 85th percentile 2. exclusion criteria subjects will be excluded from the study if he/she has: * visual or hearing defects * overweight or obese * neurological disorder * marked musculoskeletal problem

Eligibility criteria:
inclusion criteria: * age ranges from 14 to 18 years * have body mass index (bmi) = 5th percentile to less than the 85th percentile exclusion criteria: * subjects will be excluded from the study if he/she has: * visual or hearing defects * overweight or obese * neurological disorder * marked musculoskeletal problem
smoking cessation in a cohort hiv+ rio de janeiro, brazil.

Conditions: Smoking Cessation; Brachial Flow Mediated Dilatation; Nicotine Replacement Therapy

Summary: the study was carried out within a large, urban prospective cohort of plhiv at the instituto nacional de infectologia evandro chagas (ini). located in rio de janeiro, brazil, ini is a national public referral center for plwha receiving primary care since 1998. from december 2019, adults who had attitudes toward quitting smoking and had no contraindications to study pharmacotherapy were enrolled by active site searching


Eligibility criteria:
inclusion criteria: * individuals were deemed as regular smokers, defined as the consumption of one or more pack (20 cigarettes) per week in the past 6 months, and expired carbon monoxide (co) measurement \> 10 ppm at the screening visit. exclusion criteria: * previous use of transdermal nicotine patches or bupropion in the last 6 months; (ii) contraindication to nicotine patches; (iii). pregnancy; (iv) breastfeeding
tai chi exercise in patients with copd

Conditions: COPD

Summary: this is a pilot randomized controlled trial of feasibililty and prelimnary effects of a 12 week tai chi intervention vs. usual care in patients with chronic obstructive pulmonary disease


Eligibility criteria:
inclusion criteria: * physician diagnosis of copd * fev1\<65% of predicted and fev1/fvc\<70% of predicted * ≥45 years old exclusion criteria: * copd exacerbation requiring er visit or hospitalization within past month * planned major pulmonary intervention in coming 3 months * severe peripheral vascular disease/claudication or other physical condition precluding walk test * inability to perform bicycle ergometry * severe cognitive dysfunction (mmse ≤ 24) * inability to speak english * current participation in a pulmonary rehabilitation or regular practice of tai chi